Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA - Slideshow
Hansa Biopharma AB has announced an out-licensing agreement with SERB for the commercialization of Idefirix in Europe and the MENA region. This agreement is part of Hansa's strategy to expand its market presence. The details of the agreement were discussed in a recent slide deck published by the company.
- ▪Hansa Biopharma AB has entered into an out-licensing agreement with SERB.
- ▪The agreement focuses on the commercialization of Idefirix in Europe and the MENA region.
- ▪The announcement was accompanied by a slide deck detailing the agreement.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906580-hansa-biopharma-ab-publ-hnsbf-discusses-out-licensing-agreement-with-serb-for-idefirix"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
